

IRLAB announces change in share capital and number of shares following registered directed share issue

IRLAB (Nasdaq Stockholm: IRLAB A) announced today that the number of shares and votes has changed due to the directed share issue ("Share Issue"), resolved by the Board of Directors in December 2020.

Through the registration of the Share Issue, the number of class B shares and votes in IRLAB have increased with 3,250,000 shares and votes. Today, the last day of trading in the month, there are totally 51 748 406 votes and shares, of which 51 668 630 shares are of class A and 79 776 shares are of class B. Both class A and class B shares has one vote per share.

This disclosure contains information that IRLAB Therapeutics AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact person, on January 29, 2021 at 19:00 CET.

For more information

Viktor Siewertz, CFO
Tel: +46 727 10 70 70
E-mail: viktor.siewertz@irlab.se

About IRLAB

IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson's disease. The company's most advanced candidates, mesdopetam (IRL790) and pirepemate (IRL752), both of which completed Phase IIa-studies, intends to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (The Integrative Screening Process), IRLAB discovers and develops unique drug candidates for central nervous system (CNS) related disorders where large and growing medical need exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB is listed on Nasdaq Stockholm Main Market. More information on www.irlab.se.